The NAP Outcome Registry and Evidence-Generation Framework
Nutraceutical Assisted Programs
A Companion to the NAP Manifesto and Evidence Compendium The Proof Engine of the NAP Category Turning Practice into Published Evidence Michael Andrew Feller Jones Founder, Nutraceutical Assisted Programs Category
About This Document
The NAP Evidence Compendium establishes that each link in the NAP cascade is supported in the peer reviewed literature. It also states, plainly, what is not yet proven: the integrated cascade as a unified clinical hypothesis, and the comparative effectiveness of comprehensive NAP protocols against single intervention care. This document is how NAP answers those open questions — not with argument, but with data.
It defines the NAP Outcome Registry: the standardized system through which every accredited NAP center and credentialed practitioner contributes real-world clinical outcomes to a shared, governed, scientifically rigorous evidence base. It is the single most important infrastructure NAP can build, because it converts the three audiences NAP must win — skeptical clinicians, regulators, and funders — at once. An argument persuades none of them durably. A published outcome persuades all three.
This framework is offered in the same spirit as every NAP document: evidence first, honest about the limits of its own methods, and product neutral. It describes how outcomes are measured, governed, and reported, not which agents produce them.
PART I. WHY THE REGISTRY IS THE PRIORITY
1. The Credibility Ceiling
NAP today is a rigorously argued framework with a documented mechanistic basis and zero prospective outcome data of its own. That is the honest status, and it imposes a ceiling. No quantity of mechanistic citation substitutes for the demonstration that NAP protocols, delivered to real patients, produce measurable, durable improvement. Until that demonstration exists, NAP is a hypothesis dressed in evidence, and sophisticated audiences know the difference.
The registry lifts the ceiling. It is the mechanism by which NAP earns the right to be called a standard rather than a proposal.
2. Why Outcome Data Wins Every Audience
The skeptical clinician asks, "Where is your evidence that this works?" The regulator asks, "How do you know your patients are safe and helped?" The funder asks, "What is the return, and how do you measure it?" These are the same question, and the registry is the same answer: a transparent, growing body of standardized outcomes, collected prospectively, analyzed independently, and published whether the result is favorable or not.
A founder who says "trust the framework" loses all three audiences. A founder who says "here is the outcome data, including what did not work" wins the trust that no rhetoric can buy.
3. The Honesty Advantage, Operationalized
The Evidence Compendium's credibility comes from distinguishing what is proven from what is being proven. The registry is that distinction made operational. It does not assume the cascade hypothesis is true; it tests it. It does not hide protocols that underperform; it reports them and refines them. This is the difference between a movement that demands belief and a category that earns confidence.
PART II. WHAT THE REGISTRY MEASURES
4. The Core Clinical Question
The registry is designed around one falsifiable question: do patients who receive comprehensive, cascade-sequenced NAP protocols show greater and more durable improvement in validated functional and biomarker outcomes than would be expected under symptom-directed care alone? Every data element exists to answer that question.
5. Standardized Outcome Instruments
Every NAP engagement captures a common set of validated, recognized instruments at baseline and at defined intervals, so that outcomes are comparable across centers, practitioners, and conditions.
- Validated functional and psychological instruments appropriate to presentation — for example PCL-5, PHQ-9, GAD-7, recognized cognitive screens, AUDIT or DAST, and validated sleep, pain, and quality-of-life measures.
- Biomarker panels — the objective markers the NAP assessment already collects, re-tested on schedule to document terrain restoration.
- Functional milestones — the patient-meaningful outcomes that matter most: sleep restored, energy returned, work and relationships re-engaged, medication burden reduced under supervision.
- Safety signals — adverse events, tolerability, and any deterioration, captured with equal rigor (see the NAP Clinical Safety and Practice Standards).
6. Common Data Elements
To be analyzable, data must be standardized. The registry defines a minimum viable dataset that every participating center records in a common structure: de-identified demographics, presenting conditions, exposure history category, baseline instrument scores and biomarkers, the protocol phases delivered, interval re-measurements, medication changes (prescriber-supervised), adverse events, and final functional status. Centers may collect more; they may not collect less.
PART III. REGISTRY ARCHITECTURE
7. A Prospective, Pragmatic, Real-World Design
The registry is a prospective observational registry of real-world NAP practice, not a controlled trial. This is the appropriate starting design: it reflects how care is actually delivered, it generates hypotheses and effect-size estimates that justify later controlled studies, and it can begin immediately with the patients NAP already serves. Its limitations — the absence of randomization and control — are stated openly and are the reason the proof pathway (Part VI) progresses toward controlled designs.
8. The Three-Phase Build
Phase One — Single-Site Pilot. The registry begins at the founding pilot center, Operation Whole Health, within the Veterans At Ease program. A single site, a defined cohort, the common dataset, and a pre-specified analysis plan. The goal of Phase One is the first credible readout and the first peer-reviewed publication. This phase can begin now.
Phase Two — Multi-Site Accredited Network. As centers earn NAP accreditation, each joins the registry as a condition of accreditation. Multi-site data tests whether outcomes replicate across practitioners and settings — the first real evidence of generalizability.
Phase Three — Comparative and Controlled Studies. With effect-size estimates from Phases One and Two, NAP partners with academic centers to design controlled studies comparing NAP protocols to standard care, beginning in the populations where the signal is strongest. This is where the cascade hypothesis is formally tested.
9. Data Governance and Privacy
Patient data is held to the highest applicable standard across every jurisdiction NAP operates in — informed consent, de-identification for research use, secure storage, and compliance with the relevant data-protection regimes (including HIPAA and GDPR-equivalent frameworks). Patients own their data and consent explicitly to its de-identified research use; participation is never a condition of care. Data sovereignty is respected: data collected in a jurisdiction is governed by that jurisdiction's law.
PART IV. METHODOLOGY AND RIGOR
10. Pre-Specification and Honest Reporting
Every registry analysis is pre-specified: the endpoints, the cohort definition, and the analysis plan are registered before the data is examined. Results are reported whether favorable or not. Protocols that underperform are published and revised. This single commitment — to publish what does not work as readily as what does — is what separates a scientific registry from a marketing instrument, and it is non-negotiable.
11. Independent Analysis
To be credible, NAP's outcome data cannot be analyzed only by NAP. The registry commits to independent and academic-partner analysis of its data, open access to de-identified datasets for qualified researchers, and publication in peer-reviewed venues. The founder and any commercially interested party are firewalled from the analysis and interpretation of outcomes, consistent with the Charter's conflict-of-interest provisions.
12. Stating the Limits
Observational registry data establishes association and real-world effectiveness signals; it does not, by itself, establish causation. The registry says so, every time. Confounding, selection effects, and the absence of a control group are named in every report. The registry is the beginning of NAP's evidence, not its end, and the proof pathway exists precisely because the registry's design has limits that controlled studies are built to overcome.
PART V. GOVERNANCE AND ETHICS
13. Oversight
The registry operates under ethics and institutional review oversight appropriate to human-subjects research. A registry governance committee of the NAP Standards Council — including independent scientific and ethics members — oversees the dataset, approves analyses, and protects the integrity and independence of the evidence from any commercial or founder influence. The Charter's founder-specific conflict provisions apply in full.
14. The Patient at the Center
Patients are partners in the evidence, not subjects of it. They consent transparently, they may withdraw at any time without affecting their care, and the outcomes that define success are the ones that matter to them — function, capacity, and life restored — not surrogate measures chosen for convenience.
PART VI. THE PROOF PATHWAY
The registry converts NAP from argument to evidence along a defined sequence of milestones, each of which unlocks the next audience:
- Registry live at the pilot site — NAP is now generating standardized outcomes. (Unlocks: internal refinement, the first data to show partners.)
- First pre-specified pilot readout — the first real-world effect-size estimate. (Unlocks: academic interest, the case for funding.)
- First peer-reviewed publication — NAP outcomes enter the scientific record. (Unlocks: credibility with skeptics and regulators; the single highest-value milestone.)
- Multi-site replication — outcomes hold across centers. (Unlocks: the claim of generalizability; payer and policy conversations.)
- Comparative/controlled study — the cascade hypothesis formally tested against standard care. (Unlocks: recognition as an evidence-based standard of care.)
Each milestone is cheap relative to its value, and the first — a live registry at a single site — can begin with the patients NAP already serves. The framework's central recommendation is therefore simple: start the registry now, at the pilot, with the common dataset and a pre-specified analysis plan. Everything NAP wants to become depends on the data it has not yet started collecting.
CLOSING
A standard of medicine is not declared into existence. It is demonstrated. The NAP Manifesto declares the paradigm, the Evidence Compendium documents its mechanistic basis, and this framework builds the engine that will prove it in practice. The registry is where NAP stops asking to be believed and starts showing what it does.
It begins with one site, one dataset, and one honest commitment: to measure everything, to publish all of it, and to let the outcomes decide.